Company’s 36-month beta value is 0.85.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANIX is 30.39M, and currently, short sellers hold a 1.82% ratio of that floaft. The average trading volume of ANIX on April 26, 2024 was 119.40K shares.
ANIX) stock’s latest price update
Anixa Biosciences Inc (NASDAQ: ANIX) has experienced a decline in its stock price by -6.29 compared to its previous closing price of 3.18. However, the company has seen a fall of -3.87% in its stock price over the last five trading days. PRNewsWire reported 2023-12-14 that SAN JOSE, Calif., Dec. 14, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California in parallel to the 42nd Annual J.P.
ANIX’s Market Performance
Anixa Biosciences Inc (ANIX) has seen a -3.87% fall in stock performance for the week, with a -4.79% decline in the past month and a -34.22% plunge in the past quarter. The volatility ratio for the week is 7.73%, and the volatility levels for the past 30 days are at 6.05% for ANIX. The simple moving average for the past 20 days is -5.98% for ANIX’s stock, with a -17.01% simple moving average for the past 200 days.
Analysts’ Opinion of ANIX
Many brokerage firms have already submitted their reports for ANIX stocks, with Chardan Capital Markets repeating the rating for ANIX by listing it as a “Buy.” The predicted price for ANIX in the upcoming period, according to Chardan Capital Markets is $8 based on the research report published on December 23, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ANIX reach a price target of $11. The rating they have provided for ANIX stocks is “Buy” according to the report published on April 12th, 2021.
ANIX Trading at -12.60% from the 50-Day Moving Average
After a stumble in the market that brought ANIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.91% of loss for the given period.
Volatility was left at 6.05%, however, over the last 30 days, the volatility rate increased by 7.73%, as shares sank -7.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.70% lower at present.
During the last 5 trading sessions, ANIX fell by -3.87%, which changed the moving average for the period of 200-days by -6.88% in comparison to the 20-day moving average, which settled at $3.16. In addition, Anixa Biosciences Inc saw -23.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANIX starting from Titterton Lewis H jr, who purchase 15,009 shares at the price of $3.28 back on Apr 09 ’24. After this action, Titterton Lewis H jr now owns 838,037 shares of Anixa Biosciences Inc, valued at $49,230 using the latest closing price.
KUMAR AMIT, the Chief Executive Officer of Anixa Biosciences Inc, purchase 30,000 shares at $3.22 during a trade that took place back on Mar 15 ’24, which means that KUMAR AMIT is holding 491,925 shares at $96,600 based on the most recent closing price.
Stock Fundamentals for ANIX
Current profitability levels for the company are sitting at:
- -32.96 for the present operating margin
- 0.46 for the gross margin
The net margin for Anixa Biosciences Inc stands at -28.66. The total capital return value is set at -0.51. Equity return is now at value -41.01, with -40.03 for asset returns.
Based on Anixa Biosciences Inc (ANIX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -40.31. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 59.72.
Currently, EBITDA for the company is -10.96 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 257.45. The receivables turnover for the company is 0.94for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.19.
Conclusion
In a nutshell, Anixa Biosciences Inc (ANIX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
